Pharma News
This Week
Oct 7, 2025
DEG Found in Relife and Respifresh Cough Syrup in Madhya Pradesh, Reports DrugsControl Media Services
Madhya Pradesh food and drugs administration has identified Relife and Respifresh cough syrups as "unsafe" due to high levels of diethylene glycol (DEG), a toxic chemical. This follows earlier concerns regarding Coldrif syrup. The findings raise significant health risks associated with these products.
Oct 7, 2025
Eli Lilly plans to allocate $1 billion for contract manufacturing in India - The Business Times
Eli Lilly plans to invest over $1 billion in India to enhance its contract manufacturing capabilities, including a new manufacturing and quality center in Hyderabad. This investment follows President Trump's announcement of a 100% tariff on imported branded drugs. Eli Lilly aims to leverage India's skilled workforce to support its global supply network and expand its operations.
Oct 7, 2025
Major medication sparks debate over scientific colonialism - The Hindu
The antibiotic rapamycin, discovered in 1964 during the Medical Expedition to Easter Island (METEI), has become a billion-dollar success in pharmaceuticals, particularly as an immunosuppressant. However, its history raises ethical concerns about scientific colonialism and Indigenous rights, as the Rapa Nui people have not benefited from its commercialization despite their crucial role in its discovery.
Oct 6, 2025
Costco's pharmacy has begun offering weight loss medications Ozempic and Wegovy - USA Today
Costco is now offering discounted prices on Novo Nordisk's weight-loss drugs, Wegovy and Ozempic, at $499 for self-pay members. Executive members and Citibank Visa cardholders can receive an additional 2% discount. Despite competition from Eli Lilly's Zepbound and Mounjaro, Novo Nordisk aims to improve access to these GLP-1 medications, which are often not covered by employer insurance for obesity.
Oct 6, 2025
Alkermes Hit with Antitrust Lawsuit for Allegedly Trying to Prevent Generic Vivitrol from Entering the Market
Alkermes plc is facing a proposed class-action lawsuit from Value Drug Company, alleging the company illegally blocked generic versions of its opioid and alcohol dependence treatment, Vivitrol. The lawsuit claims Alkermes engaged in fraudulent patent tactics and anticompetitive settlements with Teva Pharmaceuticals and Amneal Pharmaceuticals, delaying generic market entry and inflating prices for U.S. purchasers.
Oct 6, 2025
Is AstraZeneca capable of sustaining its growth? - Investors' Chronicle
Pharmaceutical stocks surged following the US government's first 'most favoured nation' pricing agreement with Pfizer. AstraZeneca's shares rose 11%, boosting its market capitalization to ÂŁ193bn and restoring its top position on the London Stock Exchange. The company plans a direct listing in New York to strengthen its US presence, where it generates 40% of its revenue.
Oct 6, 2025
Amgen Introduces Direct-to-Patient Initiative Providing Repatha at a 60% Reduced Price
Amgen has launched a direct-to-patient program for its cholesterol drug Repatha, offering it at nearly a 60% discount to U.S. patients. This initiative comes in response to the Trump administration's efforts to reduce drug prices.
Oct 6, 2025
Recently, appetite-suppressing hormones have gained significant attention due to the launch of ...
Recent blockbuster weight-loss drugs have brought attention to appetite-suppressing hormones, highlighting their role in obesity treatment. These advancements in pharmacotherapy are reshaping approaches to weight management and obesity-related health issues.
Oct 6, 2025
MP Intensifies Efforts for Accountability in Coldrif Cough Syrup Incident - Drugs Control Media Services
Madhya Pradesh has suspended Deputy Drugs Controller Shobhit Kosta and two drugs inspectors in response to the deaths of 14 children linked to contaminated Coldrif cough syrup. This action aims to enhance accountability and address regulatory failures in the pharmaceutical oversight following the tragic incident.
Oct 6, 2025
ESPR Reaches Settlement in Nexletol/Nexlizet Patent Dispute with RDY, Shares Rise - Yahoo Finance
Esperion Therapeutics (ESPR) has settled patent litigation with Dr. Reddy’s Laboratories (RDY) regarding its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). The agreement prevents RDY from launching generics in the U.S. before April 19, 2040. Following the announcement, Esperion's shares rose 13.8%, reflecting strong sales growth for its products.
Oct 6, 2025
ESPR Reaches Settlement in Nexletol/Nexlizet Patent Dispute with RDY, Shares Rise - TradingView
Esperion Therapeutics (ESPR) has settled patent litigation with Dr. Reddy’s Laboratories (RDY) regarding its drugs Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). The agreement prevents RDY from launching generics in the U.S. before April 19, 2040. Following the announcement, Esperion's shares rose 13.8%, reflecting strong market confidence in its products.
Oct 6, 2025
Investigation of Spray Drying Techniques for the Stabilization of Peptides, Oligonucleotides, and More...
Pharmaceutical developers are set to explore spray drying technology to enhance the stability and manufacturability of peptides, oligonucleotides, and monoclonal antibodies. The upcoming session will cover innovations in spray drying, formulation strategies, and methods to maintain molecular integrity, aiming to optimize production workflows for various pharmaceutical compounds.
Oct 6, 2025
Trends and Changing Standards of Injunctions in Pharmaceutical Patent Litigation in Indian Courts
Indian courts are increasingly balancing patent rights with public health needs in pharmaceutical injunction cases. Recent rulings, including those involving drugs like Erlotinib and Sorafenib, emphasize the importance of access to affordable medicines. The judiciary's nuanced approach reflects India's role as a major generic drug supplier while fostering innovation, shaping a unique landscape in intellectual property law.
Oct 6, 2025
Aspire Biopharma submits patent application for its sublingual drug delivery system - TipRanks
Aspire Biopharma (ASBP) has filed an omnibus patent application with the U.S. Patent and Trademark Office for its advanced sublingual drug delivery technology. This application aims to protect the company's proprietary system, which enhances the pharmacokinetic performance of Active Pharmaceutical Ingredients, improving bioavailability and speed of onset.
Oct 6, 2025
Costco Pharmacy will provide Ozempic and Wegovy for a monthly fee of $499 - Mass Market Retailers
Costco is expanding its pharmacy offerings by adding weight-loss drugs Ozempic and Wegovy, priced at $499 monthly for members. This move positions Costco alongside CVS and Walmart in the growing GLP-1 market. Novo Nordisk, the manufacturer, confirmed availability at over 500 locations, aiming to enhance access to these popular medications amid rising consumer demand.
Oct 6, 2025
Eli Lilly plans to invest more than $1 billion in India to enhance its manufacturing capabilities.
Eli Lilly plans to invest over $1 billion in India to enhance manufacturing and supply through local drugmakers, focusing on key drugs for obesity, diabetes, Alzheimer's, cancer, and autoimmune conditions. The company aims to expand its presence with a new facility in Hyderabad and is actively engaging with contract manufacturers. This move follows a $5 billion investment in U.S. manufacturing.
Oct 6, 2025
J&J's Innovative Medicines Division is Well-Positioned Before Q3 Earnings Report
Johnson & Johnson (JNJ) anticipates stronger sales growth in its Innovative Medicine segment for the second half of 2025, despite challenges from the loss of exclusivity for Stelara and the Medicare Part D redesign. Key products like Darzalex, Tremfya, and Erleada are expected to drive growth, while competition from biosimilars and generics may hinder performance. JNJ's shares have risen 30.5% year-to-date.
Oct 6, 2025
Evolv introduces a peptide that activates GLP-1 receptors, marking the emergence of a new category of 'biomimetics.'
Evolv has launched a new dietary supplement, Evolv GLP-1, made from engineered baker's yeast to mimic appetite-regulating hormones GLP-1 and GIP. Unlike traditional supplements, it has a half-life of 1-2 days, offering a middle ground between quick-acting supplements and long-lasting injectable drugs like Ozempic. A 90-day human clinical study is currently underway.
Oct 6, 2025
Nobel Prize in Medicine awarded to three researchers for discovering the immune system's 'defense mechanisms' - Griffon News
Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi won the Nobel Prize in Medicine for their groundbreaking research on regulatory T-cells, which help prevent autoimmune diseases. Their discoveries have paved the way for potential treatments for autoimmune disorders and cancer. The trio will receive their award on December 10, with a total prize of $1.2 million.
Oct 6, 2025
D.C. Circuit Court Affirms That Generic Drug Manufacturers Can Exclude Patented Uses from Their Labels
The D.C. Circuit Court has upheld the legality of the "skinny label" practice, allowing generic drugmakers to omit patented uses from their labels. This ruling supports generic manufacturers in marketing non-patented indications while avoiding patent infringement, impacting future patent litigation and FDA labeling policies in the pharmaceutical industry.
Oct 6, 2025
Eli Lilly Allocates $1 Billion for Pharmaceutical Production in India - Insights and Data - IndexBox
Eli Lilly announced a $1 billion investment in India to enhance manufacturing and supply of its key drugs, including Mounjaro for obesity and treatments for diabetes and Alzheimer's. The company is collaborating with local drugmakers and establishing a facility in Hyderabad. This move aligns with global efforts to boost manufacturing capacity amid rising competition from generic drugmakers.
Oct 6, 2025
Eli Lilly invests $1 billion to enhance manufacturing in India - NewsBytes
Eli Lilly plans to invest over $1 billion in India to enhance local manufacturing and supply capabilities for key drugs, including those for obesity, diabetes, and Alzheimer's. This investment is part of Eli Lilly's global expansion strategy, as the company aims to strengthen its production capacity amid US tariff concerns. Currently, Eli Lilly relies on contract manufacturers in India.
Oct 6, 2025
Eli Lilly plans to enhance its manufacturing and supply capabilities in India through a $1 billion investment - Irish Examiner
Eli Lilly announced a $1 billion investment in India to enhance manufacturing and supply through local drugmakers, aiming to increase availability of key drugs for obesity, diabetes, Alzheimer's, cancer, and autoimmune conditions. The company is also launching a manufacturing facility in Hyderabad and expanding its contract manufacturing network amid rising competition from generic drugmakers.
Oct 5, 2025
Opening the path": Could a crucial medication resolve ongoing patent litigation disputes?
A recent ruling clarifies that in Indian patent law, a generic's failure to "clear the way" does not establish a prima facie case for injunctions. The court emphasized that the validity of a patent cannot be presumed, and such failures should only be considered when assessing the balance of convenience, as seen in cases involving AstraZeneca AB and Torrent Pharmaceuticals Limited.
Oct 5, 2025
India: Three states prohibit cough syrup following the deaths of multiple children - DW
The Indian Health Ministry has banned Coldrif cough syrup, produced by Sresan Pharma, after tests revealed it contained toxic diethylene glycol (DEG), linked to the deaths of at least nine children. Madhya Pradesh, Tamil Nadu, and Kerala have halted its sale, raising concerns over India's pharmaceutical industry, which has faced scrutiny following previous incidents involving contaminated medicines.
Oct 5, 2025
Costco Amazes Customers by Offering Wegovy and Ozempic at Half Price
Costco has partnered with Novo Nordisk to offer weight-loss drugs Wegovy and Ozempic at a reduced price of $499 for a four-week supply, significantly lower than their typical costs. However, a doctor's prescription is required, and the discount is only available for self-paying members. This initiative aims to improve access to these medications amid ongoing insurance coverage challenges.
Oct 5, 2025
Costco Teams Up with Novo Nordisk to Offer Ozempic and Wegovy | TopNews
Costco has partnered with Novo Nordisk to offer discounted pricing on semaglutide injectables, Ozempic and Wegovy, at its U.S. pharmacies. Starting October 3, eligible members can purchase a one-month supply for $499, significantly lower than typical retail prices. This initiative aims to improve access to diabetes and obesity treatments while addressing broader issues of drug affordability and healthcare delivery in the U.S.
Oct 5, 2025
Ozempic is now available in India, but its origins trace back to experiments conducted in the 1970s: The story of its development.
Novo Nordisk is set to launch its blockbuster drug Ozempic (semaglutide) in India, aimed at aiding millions with Type 2 diabetes. The once-weekly injectable, known for its blood sugar management and weight loss benefits, marks a significant expansion in treatment options for patients. This development was confirmed by Vikrant Shrotiya, the company's India Head.
